Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.

Zhao C, Gunawardana M, Villinger F, Baum MM, Remedios-Chan M, Moench TR, Zeitlin L, Whaley KJ, Bohorov O, Smith TJ, Anderson DJ, Moss JA.

Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02465-16. doi: 10.1128/AAC.02465-16. [Epub ahead of print]

PMID:
28416548
2.

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.

Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH; Consortium for Ring Adherence.

J Int AIDS Soc. 2016;19(1):20746. Review.

PMID:
27144262
3.

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings.

Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH; Consortium for Ring Adherence.

J Int AIDS Soc. 2016 May 2;19(1):20746. doi: 10.7448/IAS.19.1.20746. eCollection 2016. Review.

4.

Cell-associated transmission of HIV type 1 and other lentiviruses in small-animal models.

Moench TR.

J Infect Dis. 2014 Dec 15;210 Suppl 3:S654-9. doi: 10.1093/infdis/jiu368. Review.

5.

Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota.

O'Hanlon DE, Moench TR, Cone RA.

PLoS One. 2013 Nov 6;8(11):e80074. doi: 10.1371/journal.pone.0080074. eCollection 2013.

6.

Evaluation of microbicide gel adherence monitoring methods.

Moench TR, O'Hanlon DE, Cone RA.

Sex Transm Dis. 2012 May;39(5):335-40. doi: 10.1097/OLQ.0b013e31824790bb.

PMID:
22504592
7.

Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial.

Vincent KL, Stanberry LR, Moench TR, Breitkopf CR, Loza ML, Wei J, Grady J, Paull J, Motamedi M, Rosenthal SL.

Obstet Gynecol. 2011 Dec;118(6):1354-61. doi: 10.1097/AOG.0b013e318238f563.

8.

SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G.

PLoS One. 2011;6(9):e24095. doi: 10.1371/journal.pone.0024095. Epub 2011 Sep 15.

9.

In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide.

O'Hanlon DE, Moench TR, Cone RA.

BMC Infect Dis. 2011 Jul 19;11:200. doi: 10.1186/1471-2334-11-200.

10.

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women.

Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L; HIV Prevention Trials Network (HPTN) 035 Study Team.

AIDS. 2011 Apr 24;25(7):957-66. doi: 10.1097/QAD.0b013e32834541d9.

11.

Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse.

Moench TR, Mumper RJ, Hoen TE, Sun M, Cone RA.

BMC Infect Dis. 2010 Nov 18;10:331. doi: 10.1186/1471-2334-10-331.

12.

An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe.

Montgomery ET, Woodsong C, Musara P, Cheng H, Chipato T, Moench TR, Spielberg F, van der Straten A.

J Int AIDS Soc. 2010 Aug 5;13:30. doi: 10.1186/1758-2652-13-30.

13.

Cervicovaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilli.

O'Hanlon DE, Lanier BR, Moench TR, Cone RA.

BMC Infect Dis. 2010 May 19;10:120. doi: 10.1186/1471-2334-10-120.

14.

Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.

Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JR, Moench TR.

Drug Dev Ind Pharm. 2009 May;35(5):515-24. doi: 10.1080/03639040802488097.

15.

Hormonal contraception and the risks of STI acquisition: results of a feasibility study to plan a future randomized trial.

Hubacher D, Raymond ER, Beksinska M, Delany-Moretlwe S, Smit J, Hylton-Kong T, Moench TR.

Contraception. 2008 May;77(5):366-70. doi: 10.1016/j.contraception.2008.01.006. Epub 2008 Mar 18.

PMID:
18402854
16.

A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet.

Ballagh SA, Brache V, Mauck C, Callahan MM, Cochon L, Wheeless A, Moench TR.

Contraception. 2008 Feb;77(2):130-7. doi: 10.1016/j.contraception.2007.10.003. Epub 2007 Dec 27.

PMID:
18226678
17.

Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial.

Barnhart KT, Rosenberg MJ, MacKay HT, Blithe DL, Higgins J, Walsh T, Wan L, Thomas M, Creinin MD, Westhoff C, Schlaff W, Archer DF, Ayers C, Kaunitz A, Das S, Moench TR.

Obstet Gynecol. 2007 Sep;110(3):577-86.

PMID:
17766603
18.

Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.

Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR.

BMC Infect Dis. 2006 Jun 1;6:90.

19.

In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.

Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW.

AIDS Res Hum Retroviruses. 2005 Oct;21(10):845-53.

PMID:
16225411
20.

Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model.

Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON 3rd, Markham RB, Cone RA, Moench TR.

BMC Infect Dis. 2005 Sep 30;5:79.

Supplemental Content

Loading ...
Support Center